Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.
Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically noting the lapse of 3,132,525 options held by Director Brian Ward due to their expiry on July 23, 2025. This change reflects a reduction in Ward’s indirect holdings, which may impact the company’s governance dynamics and stakeholder perceptions, although it does not involve any financial consideration.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Ltd operates in the medical technology industry, specializing in the development and manufacturing of regenerative tissue substitutes. The company focuses on providing innovative solutions for soft tissue repair and reconstruction, aiming to improve healing outcomes in various surgical procedures.
Average Trading Volume: 233,663
Technical Sentiment Signal: Buy
Current Market Cap: A$203.6M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.